Analogic (ALOG) Inactive 10-Q8 Jun 152015 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Apr. 30, 2015	29-May-15
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Apr-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	ALOG
Entity Registrant Name	ANALOGIC CORP
Entity Central Index Key	6284
Current Fiscal Year End Date	-24
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		12,440,842

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Apr. 30, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified	Apr. 30, 2015	Jul. 31, 2014
Current assets:
Cash and cash equivalents	$119,835	$114,540
Accounts receivable, net of allowance for doubtful accounts of $1,230 and $800 as of April 30, 2015 and July 31, 2014, respectively	101,994	106,436
Inventory	145,251	124,777
Refundable and deferred income taxes	21,346	18,599
Other current assets	9,264	9,422
Total current assets	397,690	373,774
Property, plant, and equipment, net	107,746	114,165
Intangible assets, net	51,738	57,366
Goodwill	57,358	56,955
Deferred income taxes	5,280	7,475
Other assets	4,724	4,607
Total assets	624,536	614,342
Current liabilities:
Accounts payable	37,219	37,241
Accrued employee compensation and benefits	20,654	16,305
Accrued warranty	7,247	5,968
Accrued restructuring charges	799	3,431
Deferred revenue	7,633	10,761
Customer deposits	3,854	3,046
Other current liabilities	5,666	7,761
Total current liabilities	83,072	84,513
Long-term liabilities:
Accrued income taxes	2,223	5,211
Deferred income taxes	2,862	2,657
Other long-term liabilities	11,857	9,381
Total long-term liabilities	16,942	17,249
Guarantees, commitments and contingencies (Note 16)
Stockholders' equity:
Common stock, $0.05 par value; 30,000,000 shares authorized and 12,442,615 shares issued and outstanding as of April 30, 2015; 30,000,000 shares authorized and 12,372,992 shares issued and outstanding as of July 31, 2014	621	619
Capital in excess of par value	138,809	125,679
Retained earnings	388,356	378,477
Accumulated other comprehensive (loss) income	-3,264	7,805
Total stockholders' equity	524,522	512,580
Total liabilities and stockholders' equity	$624,536	$614,342

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2015	Jul. 31, 2014
In Thousands, except Share data, unless otherwise specified	Apr. 30, 2015	Jul. 31, 2014
Accounts receivable, allowance for doubtful accounts	$1,230	$800
Common stock, par value	$0.05	$0.05
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	12,442,615	12,372,992
Common stock, shares outstanding	12,442,615	12,372,992

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Net Revenue:
Product	$130,479	$122,067	$378,686	$369,992
Engineering	3,080	1,965	7,134	5,559
Total net revenue	133,559	124,032	385,820	375,551
Cost of sales:
Product	75,046	68,717	214,261	213,110
Engineering	2,560	1,961	6,114	5,067
Total cost of sales	77,606	70,678	220,375	218,177
Gross profit	55,953	53,354	165,445	157,374
Operating expenses:
Research and product development	17,156	16,915	50,950	55,795
Selling and marketing	15,928	14,338	47,283	43,603
General and administrative	15,339	12,764	42,634	40,624
Restructuring	-107	-80	-317	216
Total operating expenses	48,316	43,937	140,550	140,238
Income from operations	7,637	9,417	24,895	17,136
Other income, net	201	882	150	104
Income before income taxes	7,838	10,299	25,045	17,240
(Benefit from) provision for income taxes	-1,286	2,509	2,437	-6,089
Net income	$9,124	$7,790	$22,608	$23,329
Net income per common share:
Basic	$0.73	$0.63	$1.82	$1.88
Diluted	$0.72	$0.62	$1.79	$1.84
Weighted average shares outstanding:
Basic	12,419	12,403	12,401	12,421
Diluted	12,603	12,647	12,601	12,679
Dividends declared and paid per share	$0.10	$0.10	$0.30	$0.30

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Net income	$9,124	$7,790	$22,608	$23,329
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment, net of tax	-600	689	-10,974	1,495
Unrealized gains (losses) on foreign currency forward contracts, net of tax	339	31	-95	132
Total other comprehensive (loss) income, net of tax	-261	720	-11,069	1,627
Total comprehensive income	$8,863	$8,510	$11,539	$24,956

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$22,608	$23,329
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for (benefit from) deferred income taxes	3,271	-4,224
Depreciation and amortization	17,406	16,405
Share-based compensation expense	8,408	8,727
Writedown of inventory to net realizable value	3,706	3,111
Provision for doubtful accounts, net of recovery	430	187
Excess tax benefit from share-based compensation	-981	-3,449
Change in fair value of contingent consideration	-62	183
(Gain) loss on sale of property, plant and equipment	-101	27
Loss on purchase of investment		484
Net changes in operating assets and liabilities, exclusive of acquisition-related assets and liabilities:
Accounts receivable	1,133	18,558
Inventory	-25,680	-6,978
Other current assets	-303	753
Accounts payable	-497	7,774
Accrued liabilities	1,532	-10,008
Deferred revenue	-3,004	-92
Customer deposits	827
Accrued income taxes	-5,178	-10,095
Other liabilities	2,630	-1,574
NET CASH PROVIDED BY OPERATING ACTIVITIES	26,145	43,118
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant, and equipment	-7,193	-13,647
Acquisition of businesses, net of cash acquired	-1,600	-10,561
Purchases of marketable securities in Rabbi Trust under the Non-qualified Deferred Compensation Plan	-200	-624
Proceeds from the sale of property, plant, and equipment	264	140
NET CASH USED IN INVESTING ACTIVITIES	-8,729	-24,692
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of stock pursuant to exercise of stock options, employee stock purchase plan, restricted stock plans, and non-employee director stock plan	7,417	4,454
Repurchase of common stock	-10,242	-10,579
Dividends paid to shareholders	-3,868	-3,727
Shares repurchased for taxes for vested employee restricted stock grants	-1,731	-6,281
Excess tax benefit from share-based compensation	981	3,449
NET CASH USED IN FINANCING ACTIVITIES	-7,443	-12,684
EFFECT OF EXCHANGE RATE CHANGES ON CASH	-4,678	673
NET INCREASE IN CASH AND CASH EQUIVALENTS	5,295	6,415
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	114,540	113,033
CASH AND CASH EQUIVALENTS, END OF PERIOD	$119,835	$119,448

Business

Business	9 Months Ended
Business	Apr. 30, 2015
Business	1. Business:
	Company
	Throughout this Quarterly Report on Form 10-Q, unless the context states otherwise, the words “we,” “us,” “our” and “Analogic” refer to Analogic Corporation and all of its subsidiaries taken as a whole, and “our board of directors” refers to the board of directors of Analogic Corporation.
	Basis of Presentation
	Our unaudited consolidated financial statements presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission, or SEC, for quarterly reports on Form 10-Q. Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. We report our financial condition and results of operations on a fiscal year basis ending on July 31st of each year.
	In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2014, or fiscal year 2014, included in our Annual Report on Form 10-K as filed with the SEC on September 26, 2014. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles, or GAAP, in the United States of America.
	Consolidation
	The unaudited consolidated financial statements presented herein include our accounts and those of our subsidiaries, all of which are wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.
	In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We have not been required to consolidate the activity of any entity due to these considerations.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Apr. 30, 2015
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements
	Recently adopted
	Foreign currency matters
	In March 2013, the Financial Accounting Standards Board, or FASB, issued an update which amends guidance on foreign currency matters and consolidations to address diversity in practice related to the release of cumulative translation adjustments, or CTA, into earnings upon the occurrence of certain de-recognition events. The update reflects a compromise between the CTA release guidance included within foreign currency matters and the loss of control concepts included within consolidation guidance. It precludes the release of CTA for de-recognition events that occur within a foreign entity, unless such events represent a complete or substantially complete liquidation of the foreign entity. De-recognition events related to investments in a foreign entity result in the release of all CTA related to the derecognized foreign entity, even when a non-controlling financial interest is retained. The update also amends guidance on business combinations and for transactions that result in a company obtaining control of a business in a step acquisition by increasing an investment in a foreign entity from one accounted for under the equity method to one accounted for as a consolidated investment. This update should be applied prospectively and prior periods should not be adjusted. The update was effective for us beginning on August 1, 2014. The adoption of this standard did not have a material impact on our consolidated financial statements.
	Not yet effective
	Cloud computing arrangements
	In April 2015, the FASB issued Accounting Standards Update No. 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which amends Accounting Standards Codification, or ASC, 350, “Intangibles - Goodwill and Other.” The amendments provide guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015 and may be applied on either a prospective or retrospective basis. Early adoption is not permitted. The provisions will be effective for us in the first quarter of our fiscal year ending July 31, 2017. We do not expect the adoption of these provisions to have a material impact on our consolidated financial statements.
	Consolidation
	In February 2015, the FASB issued ASC Update No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” Update No. 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. Update No. 2015-02 is effective for annual reporting periods ending after December 15, 2015, and for annual periods and interim periods thereafter. This update is effective for us in the first quarter of fiscal year ending July 31, 2017. Early adoption is permitted. The adoption of this update is not expected to have a material impact on our financial position or results of operations.
	Revenue from contracts with customers
	In May 2014, the FASB issued an update which provides guidance for revenue recognition. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition requirement and most industry-specific guidance. This update also supersedes some cost guidance, including revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update should be applied either on a retrospective or modified retrospective basis. Early adoption is not permitted. This update will be effective for us in the first quarter of our fiscal year ending July 31, 2018. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.

Business_Combinations

Business Combinations	9 Months Ended
Business Combinations	Apr. 30, 2015
Business Combinations	3. Business Combinations
	Pathfinder Therapeutics, Inc., or Pathfinder
	On October 28, 2014, we acquired certain assets and assumed certain liabilities related to the surgical planning and guidance business of Pathfinder for $1.6 million, which was paid in cash at the acquisition date. The acquisition has been accounted for as an acquisition of a business.
	The following table summarizes the purchase price allocation based on preliminary estimates of the fair values of the separately identifiable assets acquired and liabilities assumed as of the acquisition date. We continue to obtain information to complete our valuation of these accounts and the associated tax accounting:


	(in millions)
	Inventory and receivables				$	0.2
	Goodwill					0.4
	Intangible assets:
	Developed technology (estimated useful life of 10 years)	$	0.7
	Customer relationships (estimated useful life of 2 years)		0.3
	Trade names (estimated useful life of 5 years)		0.1

	Total intangible assets					1.1

	Total assets acquired					1.7
	Accrued liabilities		(0.1	)

	Total liabilities assumed					(0.1	)

	Total purchase price				$	1.6

	We estimated the fair value of identifiable acquisition-related intangible assets primarily based on discounted cash flows projections that will arise from these assets. We use significant judgment with regard to assumptions used in the determination of fair value such as discount rates and the determination of the estimated useful lives of the intangible assets.
	The total weighted average amortization period for the intangible assets is approximately 7.6 years. Goodwill associated with the acquisition was primarily attributable to the opportunities from the addition of Pathfinder’s product portfolio and technology which complement our suite of products. The goodwill from this acquisition will be deductible for tax purposes over the statutory 15 year period.

	During the nine months ended April 30, 2015, we incurred acquisition costs of approximately $0.1 million which consisted primarily of legal and due diligence expenses that are included in our general and administrative expenses in our Consolidated Statements of Operations.
	The pro forma financial information for the three and nine months ended April 30, 2015, including revenue and net income, is immaterial, and has not been separately presented.
	PocketSonics, Inc., or PocketSonics
	In April 2010, we entered into an agreement with PocketSonics, a privately-held ultrasound technology company based in Charlottesville, Virginia, which granted us an exclusive license to certain ultrasound technology owned or controlled by PocketSonics and a ten percent (10%) equity interest in PocketSonics. The equity investment was recorded as in-process research and development, or IPR&D, of $1.9 million. Since that time, we have collaborated with PocketSonics to develop patented ultrasound technology to enable the acceleration of high acuity guided procedures to lower cost point-of-care settings and other technical applications. On September 20, 2013, we acquired all of the remaining stock of PocketSonics. The purchase price includes base consideration of $11.1 million paid in cash at closing, fair value of contingent consideration of $1.9 million, and revaluation of our initial equity investment. We undertook this acquisition to further strengthen our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The acquisition was funded from our existing cash on hand and has been accounted for as an acquisition of a business.
	The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:


	(in millions)
	Cash				$	0.5
	Goodwill					6.9
	IPR&D					11.5

	Total assets acquired					18.9
	Accounts payable and accrued expenses	$	(0.3	)
	Deferred taxes		(4.1	)

	Total liabilities assumed					(4.4	)

	Total purchase price				$	14.5

	In determining the fair value, we considered, among other factors, market participants’ intentions to use the acquired assets and the historical and estimated future demand for PocketSonics products and services. We recognized an IPR&D asset of $11.5 million. The fair value of the asset was determined by a probability adjusted cash flow analysis. In May 2014, we determined that the IPR&D was completed and reclassified as developed technology that is being amortized over its estimated useful life of 10 years.
	In connection with this acquisition, we recorded a fair value contingent consideration obligation of $2.0 million as of April 30, 2015, with potential exposure of up to $3.0 million payable upon the achievement of certain milestones relating to the PocketSonics technology. The contingent earn-out payments to the sellers of PocketSonics would be payable upon commercial launch and achievement of volume sales target as defined in the asset purchase agreement. The $2.0 million fair value was estimated through a valuation model that incorporates probability adjusted assumptions relating to the achievement of these milestones and the likelihood of us making payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 input measurement. Subsequent changes in the fair value of this obligation will be recognized as adjustments to the contingent consideration liability and reflected within our Consolidated Statements of Operations within selling and marketing expenses. For additional information related to the fair value of this obligation, please refer to Note 7, Fair Value Measurements.
	We also recorded a goodwill asset of $6.9 million, representing the value of the opportunity of further strengthening our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The goodwill will not be deductible for tax purposes.
	We recognized a loss of $0.5 million related to our 10% pre-acquisition equity interest, which is reflected as a component of other expense, net within our Consolidated Statements of Operations during the nine months ended April 30, 2014.
	During the nine months ended April 30, 2014, we incurred acquisition costs of approximately $0.1 million which consisted primarily of legal and due diligence expenses that are included in our general and administrative expenses in our Consolidated Statements of Operations.

Accounts_Receivable_Net

Accounts Receivable, Net	9 Months Ended
Accounts Receivable, Net	Apr. 30, 2015
Accounts Receivable, Net	4. Accounts Receivable, Net
	Our accounts receivable arise primarily from products sold and services provided in North America, Europe and Asia. The balance in accounts receivable represents the amount due from our domestic and foreign original equipment manufacturers, or OEM, customers, distributors and end users. We perform ongoing credit evaluations of our customers’ financial condition and continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon specific customer collection issues that have been identified. We accrue reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. To date, our historical write-offs of accounts receivable have been minimal.
	Our top ten customers combined accounted for approximately 68% of our total net revenue for each of the three months ended April 30, 2015 and 2014 and 64% and 67% of our total net revenue for the nine months ended April 30, 2015 and 2014, respectively. Set forth in the table below are customers which individually accounted for 10% or more of our net revenue.


		Three Months Ended						Nine Months Ended
		April 30,						April 30,
		2015			2014			2015			2014
	Koninklijke Philips Electronics N.V., or Philips		15	%		17	%		13	%		17	%
	L-3 Communications Corporation, or L-3		15	%		12	%		13	%		11	%
	Toshiba Corporation, or Toshiba		12	%		10	%		12	%		11	%
	Siemens AG		11	%		12	%		12	%		11	%
	The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:


		As of			As of
		April 30,			July 31,
		2015			2014
	L-3		20	%		16	%
	Philips		18	%		16	%
	Toshiba		*			11	%
	Note(*): Total net accounts receivable due from customer was less than 10% in this period.

Inventory

Inventory	9 Months Ended
Inventory	Apr. 30, 2015
Inventory	5. Inventory
	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:


	(in millions)	As of		As of
		April 30,		July 31,
		2015		2014
	Raw materials	$	70.9	$	59.6
	Work in process		51.3		41.2
	Finished goods		23.1		24

	Total inventory	$	145.3	$	124.8

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
Goodwill and Intangible Assets	Apr. 30, 2015
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets
	Goodwill
	Analogic has goodwill balances of $57.4 million and $57.0 million at April 30, 2015 and July 31, 2014, respectively. The difference between the two periods relates to goodwill associated with the acquisition of Pathfinder of $0.4 million. The business acquired from Pathfinder is included under our Security and Detection segment. Please refer to Note 3. Business Combinations for more information on the acquisition of Pathfinder.

	Intangible assets
	Intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, and trade names. The estimated useful lives for all of these intangible assets, excluding a trade name determined to have an indefinite life, range between 1 to 14 years. Intangible assets are summarized as follows:


					As of April 30, 2015						As of July 31, 2014
	(in millions)		Weighted		Cost		Accumulated		Net		Cost		Accumulated		Net
			Average				Amortization						Amortization
			Amortization
			Period
	Developed technologies			10 years	$	30.3	$	11.5	$	18.8	$	29.6	$	9	$	20.6
	Customer relationships			13 years		44.2		19.1		25.1		43.9		15.1		28.8
	Trade names*			3 years		8.6		0.8		7.8		8.5		0.5		8
	Total intangible assets				$	83.1	$	31.4	$	51.7	$	82	$	24.6	$	57.4

	*	- $7.6 million of trade names are non-amortizable as of April 30, 2015 and July 31, 2014.
	Amortization expense related to acquired intangible assets was $2.2 million and $6.6 million for the three and nine months ended April 30, 2015, respectively. Amortization expense related to acquired intangible assets was $1.9 million and $5.7 million for the three and nine months ended April 30, 2014, respectively.
	The estimated future amortization expense related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:


	(in millions)		Estimated
			Future
			Amortization
			Expense
	2015 (remaining three months)		$	2.2
	2016			8
	2017			7.2
	2018			6.2
	2019			5
	Thereafter			15.5

			$	44.1

	We performed the annual impairment test for our goodwill and other intangible assets with indefinite lives as of December 31, 2014. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value and as a basis for determining whether it is necessary to perform the qualitative impairment test. Alternatively, we may elect to bypass the qualitative assessment and proceed to the two-step quantitative impairment test. Our quantitative impairment assessment considered both the market approach and income approach to calculate the fair value of a reporting unit, with different probabilities assigned to each. Under the market approach, the fair value of the reporting unit is based on trading multiples and a control premium, which was determined based on an analysis of control premiums for recent relevant acquisitions. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows. The income approach is dependent on a number of significant management assumptions including estimates of future sales, future gross margin and operating margin percentages, and discount rates. We determined that the fair values of our reporting units were in excess of their carrying values, and concluded that there was no impairment.
	We compared the fair value of a trade name that has an indefinite life using the relief from royalty approach to its carrying value as of December 31, 2014. The relief from royalty approach utilized an after-tax royalty rate and a discount rate. The after-tax royalty rate was determined based on royalty research and margin analysis while the discount rate was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales for the trade name. We determined that the fair value of the trade name was in excess of its carrying value.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Apr. 30, 2015
Fair Value Measurements	7. Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in a principal or the most advantageous market for the asset transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

		•		Level 1 – Quoted prices in active markets for identical assets or liabilities.

		•		Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

		•		Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table provides the assets and liabilities carried at fair value and measured on a recurring basis at April 30, 2015 and July 31, 2014:


			Fair Value Measurements at April 30, 2015
	(in millions)		Total		Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets
	Plan assets for deferred compensation		$	4.2	$	4.2	$	-	$	-
	Total assets at fair value		$	4.2	$	4.2	$	-	$	-
	Liabilities
	Contingent consideration		$	2	$	-	$	-	$	2
	Foreign currency forward contracts			0.1		-		0.1		-
	Total liabilities at fair value		$	2.1	$	-	$	0.1	$	2

			Fair Value Measurements at July 31, 2014
	(in millions)		Total		Quoted Prices		Significant		Significant
					in Active		Other		Unobservable
					Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets
	Plan assets for deferred compensation		$	3.6	$	3.6	$	-	$	-
	Total assets at fair value		$	3.6	$	3.6	$	-	$	-
	Liabilities
	Contingent consideration		$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value		$	2.1	$	-	$	-	$	2.1
	Assets held in the deferred compensation plan will be used to pay benefits under our non-qualified deferred compensation plan. The investments primarily consist of mutual funds which are publicly traded on stock exchanges. Accordingly, the fair value of these assets is categorized as Level 1 within the fair value hierarchy.
	The fair value of the liabilities arising from our foreign currency forward contracts is determined by valuation models based on market observable inputs, including forward and spot prices for currencies. Accordingly, the fair value of these liabilities is categorized as Level 2 within the fair value hierarchy.
	The fair value of our contingent consideration obligation is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of this liability is categorized as Level 3 within the fair value hierarchy.
	The fair value of the contingent payments associated with the acquisition of PocketSonics was calculated utilizing 100% probability for the earn out associated with the Section 510(k) clearance obtained from the Food and Drug Administration, or FDA, on April 9, 2014 and the anticipation of commercial sales, as defined in the purchase agreement, in the fiscal year ending July 31, 2016, or fiscal year 2016. Each quarter we revalue the contingent consideration obligations associated with the acquisition of PocketSonics to its then current fair value and record changes in the fair value to the Consolidated Statements of Operations. Changes in contingent consideration result from changes in the assumptions regarding probabilities of the estimated timing of launch, volume sales target, payments and the discount rate used to estimate the fair value of the liability. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value. There was no change in fair value during the three months ended April 30, 2015. There was a $0.1 million decrease in the fair value of our contingent consideration obligation during the nine months ended April 30, 2015. As of April 30, 2015 and July 31, 2014 the fair value of the contingent consideration obligation was reported in Other long-term liabilities and Other current liabilities, respectively, in the Consolidated Balance Sheets.

Derivative_Instruments

Derivative Instruments	9 Months Ended
Derivative Instruments	Apr. 30, 2015
Derivative Instruments	8. Derivative Instruments
	Certain of our foreign operations have revenue and expenses transacted in currencies other than the U.S. dollar. In order to mitigate foreign currency exchange risk, we use forward contracts to lock in exchange rates associated with a portion of our forecasted international expenses.
	As of April 30, 2015, we had forward contracts outstanding denominated in Canadian dollars with notional amounts totaling $2.7 million. These contracts have been designated as cash flow hedges and the unrealized loss of $0.1 million, net of tax, on these contracts is reported in Accumulated other comprehensive loss in the Consolidated Balance Sheet. As of April 30, 2015, the fair value of derivatives designated as hedging instruments are presented in Other current liabilities on our Consolidated Balance Sheet. There were no outstanding derivatives as of July 31, 2014. Realized gains and losses on the cash flow hedges are recognized in cost of sales and operating expenses in our Consolidated Statements of Operations in the period when the payment of expenses is recognized. During both the three and nine months ended April 30, 2015, the realized loss on the cash flow hedges was $0.3 million. During the three and nine months ended April 30, 2014, the realized gain (loss) on the cash flow hedges were $0.1 million and $(0.2) million, respectively. We expect all contracts currently outstanding to settle as of July 31, 2015 and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to cost of sales and operating expenses.

Common_Stock_Repurchases

Common Stock Repurchases	9 Months Ended
	Apr. 30, 2015
Common Stock Repurchases	9. Common Stock Repurchases
	On June 2, 2014, our board of directors authorized the repurchase of up to $30.0 million of our common stock. Repurchases under this program will be funded by our available cash. The repurchase program does not have a fixed expiration date. During the three and nine months ended April 30, 2015, we repurchased and retired 37,840 and 132,323 shares of common stock under this repurchase program for $3.3 million and $10.2 million, at an average purchase price of $86.68 and $77.37 per share, respectively. Through April 30, 2015, in total we have repurchased and retired 151,006 shares of common stock under this repurchase program for $11.7 million at an average purchase price of $77.23 per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Apr. 30, 2015
Accumulated Other Comprehensive Income	10. Accumulated Other Comprehensive Income
	Components of comprehensive income include net income and certain transactions that have generally been reported in the Consolidated Statements of Changes in Stockholders’ Equity. Other comprehensive income consists of reported foreign currency translation gains and losses (net of taxes), actuarial gains and losses on pension plan assets (net of taxes), and changes in the unrealized value on foreign currency forward contracts (net of taxes). Deferred taxes are not provided on cumulative translation adjustments where we expect earnings of a foreign subsidiary to be indefinitely reinvested. The income tax effect of currency translation adjustments related to foreign subsidiaries that are not considered indefinitely reinvested is recorded as a component of deferred taxes with an offset to other comprehensive income.
	The following table summarizes components of Accumulated other comprehensive (loss) income for the nine months ended April 30, 2015:


	(in millions)	Unrealized			Unrealized			Currency			Accumulated
		Losses			Losses on			Translation			Other
		on Foreign			Pension Plan			Adjustment			Comprehensive
		Currency									Income (Loss)
		Forward
		Contracts
	Balance at July 31, 2014	$	-		$	(3.6	)	$	11.4		$	7.8
	Pre-tax change before reclassification to earnings		(0.1	)		-			(10.9	)		(11.0	)
	Income tax benefit		-			-			(0.1	)		(0.1	)
	Balance at April 30, 2015	$	(0.1	)	$	(3.6	)	$	0.4		$	(3.3	)

	The ineffective portion of the unrealized losses on foreign currency forward contracts and unrealized gains or losses on currency translation adjustment are included in other expense, net on our Consolidated Statements of Operations.

Sharebased_Compensation

Share-based Compensation	9 Months Ended
Share-based Compensation	Apr. 30, 2015
Share-based Compensation	11. Share-based Compensation
	The following table presents share-based compensation expense included in our Consolidated Statements of Operations:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Cost of product sales		$	0.2		$	0.1		$	0.5		$	0.5
	Cost of engineering sales			0.1			0.1			0.2			0.3
	Research and product development			0.7			0.5			2			2
	Selling and marketing			0.4			0.3			1.1			0.9
	General and administrative			2			1.9			4.6			5
	Total share-based compensation expense before tax			3.4			2.9			8.4			8.7
	Income tax effect			(1.0	)		(0.9	)		(2.5	)		(2.7	)
	Share-based compensation expense included in net income		$	2.4		$	2		$	5.9		$	6
	Stock options
	We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of our stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and our expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
	We granted 78,846 stock options during the nine months ended April 30, 2015. We did not grant any stock options during the three months ended April 30, 2015. The fair value of each option granted during the nine months ended April 30, 2015 and during the three and nine months ended April 30, 2014 was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
			2015			2014			2015			2014
	Expected option term in years (1)			-			5.31			5.31			5.37
	Expected volatility (2)			-			35.1	%		29.3	%		38.6	%
	Risk-free interest rate (3)			-			1.51	%		1.82	%		1.77	%
	Expected annual dividend yield (4)			-			0.42	%		0.56	%		0.52	%
	Weighted average grant date fair value			-		$	30.8		$	19.95		$	27.55

	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk free interest rate for periods equal to the expected term of the stock option is based on the U.S. Treasury yield curve in effect at the time of grant.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
	The total intrinsic value of options exercised during the three and nine months ended April 30, 2015 was $2.5 million and $4.2 million, respectively.
	As of April 30, 2015, 295,878 stock options were vested or expected to vest and 143,207 stock options were exercisable. These options have a weighted average exercise price of $68.50 and $63.52, respectively, aggregate intrinsic value of $4.7 million and $3.0 million, respectively, and a weighted average remaining contractual term of 5.07 years and 4.37 years, respectively.

	Restricted stock and restricted stock units
	We granted 206 and 28,455 relative total shareholder return, or TSR, performance-based awards and 265 and 36,641 non-GAAP earnings per share, or EPS, performance-based awards during the three and nine months ended April 30, 2015, respectively. The fair value of our non-GAAP EPS performance-based awards was estimated using the quoted closing price of our common stock on the date of grant. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
			2015			2014			2015			2014
	Stock price (1)		$	87.5		$	94.32		$	71.33		$	77.14
	Expected volatility (2)			27.6	%		27.5	%		29.3	%		27.6	%
	Risk-free interest rate (3)			0.83	%		0.46	%		1	%		0.82	%
	Expected annual dividend yield (4)			0	%		0	%		0	%		0	%
	Weighted average grant date fair value of performance based restricted stock awards		$	127.52		$	117.61		$	88		$	93.85

	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk free interest rate for periods equal to the performance period is based on the U.S. Treasury yield curve in effect at the time of grant.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.
	The total fair value of restricted stock units, or RSU’s, that vested during the three and nine months ended April 30, 2015 was $1.1 million and $6.5 million, respectively.
	As of April 30, 2015, the unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock was $12.7 million. This cost will be recognized over an estimated weighted average amortization period of 1.4 years and assumes target performance for the non-GAAP EPS performance-based RSU’s.

Restructuring_Charges

Restructuring Charges	9 Months Ended
Restructuring Charges	Apr. 30, 2015
Restructuring Charges	12. Restructuring Charges
	Fiscal Year 2014 Restructuring Plan
	During the fourth quarter of fiscal year 2014, we implemented our fiscal year 2014 restructuring plan to improve our operational effectiveness in Peabody, Massachusetts and leverage core competencies better across the business. We incurred pre-tax charges of $2.6 million from the time that we implemented the plan during the fourth quarter of fiscal year 2014 through April 30, 2015, primarily relating to severance and personnel related costs for involuntarily terminated employees. We expect that the restructuring plan will be substantially completed during fiscal year 2015. During the nine months ended April 30, 2015, we recorded a reduction of $0.2 million in our restructuring costs.
	Fiscal Year 2013 Restructuring Plan
	In May 2013, we announced our fiscal year ended July 31, 2013, or fiscal year 2013, restructuring plan and incurred pre-tax charges of $4.0 million through April 30, 2015, primarily relating to severance and personnel related costs of terminated employees, facility exit costs for the closure of the Ultrasonix sales subsidiary in Paris, France, and the closure of our ultrasound transducer operation in Englewood, Colorado as we consolidate our transducer operations in State College, Pennsylvania. This plan also includes activities to consolidate manufacturing and certain support functions currently conducted in our Ultrasonix facility in Vancouver, Canada with our other facilities, as well as optimization of our operations in Montreal, Canada and Peabody, Massachusetts. During the nine months ended April 30, 2015, we incurred $(0.1) million related to the Englewood, Colorado facility. We expect that the restructuring plan will be completed in fiscal year 2017 when the lease on the Englewood, Colorado facility ends.

	Current Period Activity
	The following table summarizes accrued restructuring activities for the three months ended April 30, 2015:


	(in millions)		Employee			Facility			Total
			Severance			Exit
			and Benefits (A)			Costs (B)
	Balance at January 31, 2015		$	1.1		$	0.5		$	1.6
	Adjustments			(0.1	)		-			(0.1	)
	Cash payments			(0.5	)		(0.1	)		(0.6	)
	Balance at April 30, 2015		$	0.5		$	0.4		$	0.9
	The following table summarizes accrued restructuring activities for the nine months ended April 30, 2015:


	(in millions)		Employee			Facility			Acquisition			Total
			Severance			Exit			Related
			and Benefits (A)			Costs (B)			Charges (B)
	Balance at July 31, 2014		$	2.9		$	0.8		$	0.1		$	3.8
	Adjustments			(0.2	)		(0.1	)		-			(0.3	)
	Cash payments			(2.2	)		(0.3	)		(0.1	)		(2.6	)
	Balance at April 30, 2015		$	0.5		$	0.4		$	-		$	0.9

	(A)	All activity during the period pertains to the 2014 Restructuring Plan.
	(B)	All activity during the period pertains to the 2013 Restructuring Plan.
	Restructuring and related charges, including actions associated with acquisitions, by segment are as follows:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Medical Imaging		$	(0.1	)	$	-		$	(0.2	)	$	(0.2	)
	Ultrasound			-			(0.1	)		(0.1	)		0.4
	Total restructuring and related charges		$	(0.1	)	$	(0.1	)	$	(0.3	)	$	0.2
	Accrued restructuring charges are classified on the Consolidated Balance Sheets in the following location:


	(in millions)		As of			As of
			April 30,			July 31,
			2015			2014
	Accrued restructuring charges		$	0.8		$	3.4
	Other long-term liabilities			0.1			0.4
	Total restructuring and related charges		$	0.9		$	3.8

Net_Income_Per_Common_Share

Net Income Per Common Share	9 Months Ended
Net Income Per Common Share	Apr. 30, 2015
Net Income Per Common Share	13. Net Income Per Common Share
	Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including unvested restricted stock and the assumed exercise of stock options using the treasury stock method.

	Basic and diluted net income per share are calculated as follows:


		Three Months Ended				Nine Months Ended
		April 30,				April 30,
	(in millions, except share data)	2015		2014		2015		2014
	Net income	$	9.1	$	7.8	$	22.6	$	23.3

	Weighted average number of common shares outstanding-basic (000’s)		12,419		12,403		12,401		12,421
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)		184		244		200		258
	Weighted average number of common shares outstanding-diluted (000’s)		12,603		12,647		12,601		12,679

	Basic net income per share	$	0.73	$	0.63	$	1.82	$	1.88
	Diluted net income per share	$	0.72	$	0.62	$	1.79	$	1.84

	Anti-dilutive shares related to outstanding stock options and unvested restricted stock (000’s)		16		123		179		109

Income_Taxes

Income Taxes	9 Months Ended
Income Taxes	Apr. 30, 2015
Income Taxes	14. Income Taxes
	The following table presents the (benefit from) provision for income taxes and our effective tax rate for the three and nine months ended April 30, 2015 and 2014:


		Three Months Ended						Nine Months Ended
		April 30,						April 30,
	(in millions)	2015			2014			2015			2014
	(Benefit from) provision for income taxes	$	(1.3	)	$	2.5		$	2.4		$	(6.1	)
	Effective tax rate		-16	%		24	%		10	%		-35	%
	The effective income tax rate on operations is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.
	Our effective tax rate for the three and nine months ended April 30, 2015 is lower than the statutory rate of 35% primarily due to income generated outside the United States in countries with lower tax rates, the U.S. manufacturing deduction, and tax credits in the U.S. and Canada. The tax (benefit) provision for the three and nine months ended April 30, 2015 includes discrete tax benefits totaling $2.9 million and $3.7 million, respectively. The discrete items for the three months ended April 30, 2015 consist of $3.0 million in favorable changes in reserves for uncertain tax positions partially offset by $0.1 million in miscellaneous unfavorable discrete items. The discrete tax benefit for the nine months ended April 30, 2015, consists primarily of $3.0 million in favorable changes in reserves for uncertain tax positions and $0.8 million in favorable benefit for the extension of U.S. Federal tax credits for research and development, or R&D, offset in part by $0.1 million in miscellaneous unfavorable discrete items.
	Our effective tax rate before discrete items for the three and nine months ended April 30, 2014, respectively, was lower than the statutory rate of 35%, primarily due to lower foreign tax rates, and tax credits in the U.S. and Canada. The tax provision for the nine months ended April 30, 2014 includes certain discrete tax benefits totaling $10.6 million. The discrete items for the three months ended April 30, 2014 consist of $0.2 million in favorable changes in reserves for uncertain tax positions resulting from accretion of interest, expiration of the statute of limitations and other items, as well as $0.6 million for an unfavorable adjustment to a deferred item related to equity compensation, and $0.4 million in miscellaneous favorable discrete items. The discrete tax benefit for the nine months ended April 30, 2014, consists primarily of a reduction in a net deferred tax liability of $8.8 million associated with a change in classification of our Canadian operations, and a reduction in uncertain tax positions primarily associated with federal tax credits for R&D of $0.9 million following the conclusion of the Internal Revenue Service, or IRS, review for the fiscal year 2009, along with $0.9 million of other items.
	We are subject to U.S. Federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of April 30, 2015, we have concluded all U.S. Federal income tax matters through the year ended July 31, 2011. We accrue interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At April 30, 2015 and July 31, 2014, we had approximately $0.3 million and $0.6 million, respectively, accrued for interest and penalties on unrecognized tax benefits.
	At April 30, 2015, we had $4.4 million of unrecognized tax benefits for uncertain tax positions and $0.3 million of related accrued interest and penalties. We are unable to reasonably estimate the amount and period in which these liabilities might be paid.

Segment_Information

Segment Information	9 Months Ended
Segment Information	Apr. 30, 2015
Segment Information	15. Segment Information
	Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security and Detection. Our business segments are described as follows:

		•		Medical Imaging primarily includes systems and subsystems for Computed Tomography, or CT, and Magnetic Resonance Imaging, or MRI, medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography.

		•		Ultrasound includes ultrasound systems and transducers primarily in the urology, surgery, anesthesia, and other point-of-care markets.

		•		Security and Detection, formerly known as Security Technology, primarily includes advanced CT threat detection systems used in checked baggage screening at airports worldwide.
	The tables below present information about our reportable segments:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Product revenue:
	Medical Imaging		$	70.8		$	70.7		$	209		$	208.3
	Ultrasound			37.8			37.3			116.8			112.1
	Security and Detection			21.9			14.1			52.9			49.6
	Total product revenue		$	130.5		$	122.1		$	378.7		$	370
	Engineering revenue:
	Medical Imaging		$	1.1		$	1		$	2.8		$	3.2
	Ultrasound			0.8			-			2			-
	Security and Detection			1.2			1			2.3			2.4
	Total engineering revenue		$	3.1		$	2		$	7.1		$	5.6
	Net revenue:
	Medical Imaging		$	71.9		$	71.7		$	211.8		$	211.5
	Ultrasound			38.6			37.3			118.8			112.1
	Security and Detection			23.1			15.1			55.2			52
	Total net revenue		$	133.6		$	124.1		$	385.8		$	375.6
	Income from operations:
	Medical Imaging		$	8.5		$	8.9		$	25.4		$	19.3
	Ultrasound			(4.2	)		(1.3	)		(7.1	)		(6.1	)
	Security and Detection			3.3			1.8			6.6			3.9
	Total income from operations			7.6			9.4			24.9			17.1
	Total other income, net			0.2			0.9			0.1			0.1
	Income before income taxes		$	7.8		$	10.3		$	25		$	17.2


			As of			As of
			April 30,			July 31,
	(in millions)		2015			2014
	Identifiable assets by segment:
	Medical Imaging		$	191.6		$	218.5
	Ultrasound			230			235.5
	Security and Detection			49			35
	Total reportable segment assets			470.6			489
	Corporate assets (A)			153.9			125.3
	Total assets		$	624.5		$	614.3


			As of			As of
			April 30,			July 31,
	(in millions)		2015			2014
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			55.1			55.1
	Security and Detection (B)			0.4			-
	Total goodwill		$	57.4		$	57

	(A)	Includes cash and cash equivalents of $82.8 million and $60.9 million as of April 30, 2015 and July 31, 2014, respectively.
	(B)	Includes goodwill related to the Pathfinder acquisition as described in Note 3, Business Combinations.

Guarantees_Commitments_and_Con

Guarantees, Commitments and Contingencies	9 Months Ended
	Apr. 30, 2015
Guarantees, Commitments and Contingencies	16. Guarantees, Commitments and Contingencies
	Guarantees and Indemnification Obligations
	Our standard OEM and supply agreements entered in the ordinary course of business typically contain an indemnification provision pursuant to which we indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments we could be required to make under these indemnification provisions is, in some instances, unlimited. Our costs to defend lawsuits or settle claims related to these indemnification agreements have been insignificant to date. As a result, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these agreements as of April 30, 2015.
	Generally, we warrant that our products will perform in all material respects in accordance with our standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 60 months from the date of delivery. We provide for the estimated cost of product and service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable.
	The following table presents our product warranty liability as of April 30, 2015:


	(in millions)		As of
			April 30,
			2015
	Balance at July 31, 2014		$	6
	Provision			4.8
	Settlements made in cash or in kind during the period			(3.6	)
	Balance at April 30, 2015		$	7.2
	At April 30, 2015 and July 31, 2014, we had deferred revenue for extended product warranty contracts of $5.6 million and $7.4 million, respectively.

	Revolving Credit Agreements
	On October 11, 2011, we entered into a five-year, revolving credit agreement, or Credit Agreement, with the financial institutions identified therein as lenders, which included Santander Bank, TD Bank, N.A., and HSBC Bank USA, National Association. The Credit Agreement provides $100.0 million in available credit and expires on October 10, 2016, when all outstanding borrowings will be payable in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty.
	Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $150.0 million in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the credit facility are guaranteed by our material domestic subsidiaries and are supported by a pledge of 65% of the capital stock and equity equivalents of our principal international subsidiary.
	Interest rates on borrowings outstanding under the credit facility range from 1.25% to 2.00% above the LIBOR rate, or, at our option range from 0.00% to 1.00% above the defined base rate, in each case based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio.
	The Credit Agreement limits us and our subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios:

		•		A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters earnings before interest, taxes, depreciation and amortization, or EBITDA, of no greater than 2.75:1.00 at any time; and

		•		An interest coverage ratio, defined as the ratio of consolidated trailing four quarters EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.
	As of April 30, 2015 our leverage ratio was 0.004 and our interest coverage ratio was not applicable as we had no attributable interest expense. As of April 30, 2015, we were in full compliance with all financial and operating covenants contained in the Credit Agreement.
	Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.
	In connection with entering into the Credit Agreement, we incurred approximately $0.5 million of transactions costs, which are being expensed over the five-year life of the credit facility.
	As of April 30, 2015 and July 31, 2014, we had approximately $1.2 million and $4.4 million, respectively, in other revolving credit facilities with banks available for direct borrowings. We did not have any borrowing outstanding under credit facilities at April 30, 2015 and July 31, 2014.
	Legal Claims
	We are subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business. Although legal proceedings are inherently unpredictable, we believe that we have valid defenses with respect to those matters currently pending against us and intend to defend ourselves vigorously. The outcome of these matters, individually and in the aggregate, is not expected to have a material impact on our cash flows, results of operations, or financial position. In addition to litigation claims, investigations, and audits arising in the normal course of business, we are also subject to an investigation regarding our Danish subsidiary. Please refer to the following disclosure for more details regarding the investigation of our Danish subsidiary. We record losses when estimable and probable in accordance with U.S. GAAP.
	Investigation Regarding our Danish Subsidiary
	As initially disclosed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2011, we identified certain transactions involving our Danish subsidiary BK Medical ApS, or BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law, including Danish law and the U.S. Foreign Corrupt Practices Act, and our business policies. These have included transactions in which the distributors paid BK Medical amounts in excess of amounts owed and BK Medical transferred the excess amounts, at the direction of the distributors, to third parties identified by the distributors. We have terminated the employment of certain BK Medical employees and also terminated our relationships with the BK Medical distributors that were involved in the transactions. We have concluded that the transactions identified to date have been properly accounted for in our reported financial statements in all material respects. However, we have been unable to ascertain with certainty the ultimate beneficiaries or the purpose of these transfers. We have voluntarily disclosed this matter to the Danish Government, the U.S. Department of Justice, or DOJ, and the SEC, and are cooperating with inquiries by the Danish Government, the DOJ and the SEC. We believe that the SEC and DOJ have substantially completed their investigation into the transactions at issue and that it is reasonably likely that one or both of these entities may seek to impose sanctions and/or penalties on us in connection with a resolution of their inquiries. We are unable to estimate the potential penalties and/or sanctions that may ultimately be assessed. During the three and nine months ended April 30, 2015, we incurred inquiry-related costs of approximately $0.3 million and $1.4 million, respectively, in connection with this matter. During the three and nine months ended April 30, 2014, we incurred inquiry-related costs of approximately $0.4 million and $1.3 million, respectively, in connection with this matter.

Subsequent_Event

Subsequent Event	9 Months Ended
	Apr. 30, 2015
Subsequent Event	17. Subsequent Event
	We declared a dividend of $0.10 per share of common stock on June 1, 2015, which will be paid on June 29, 2015 to stockholders of record on June 15, 2015.

Business_Combinations_Tables

Business Combinations (Tables)	9 Months Ended
Business Combinations (Tables)	Apr. 30, 2015
Pathfinder Therapeutics Inc
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	The following table summarizes the purchase price allocation based on preliminary estimates of the fair values of the separately identifiable assets acquired and liabilities assumed as of the acquisition date. We continue to obtain information to complete our valuation of these accounts and the associated tax accounting:


	(in millions)
	Inventory and receivables				$	0.2
	Goodwill					0.4
	Intangible assets:
	Developed technology (estimated useful life of 10 years)	$	0.7
	Customer relationships (estimated useful life of 2 years)		0.3
	Trade names (estimated useful life of 5 years)		0.1

	Total intangible assets					1.1

	Total assets acquired					1.7
	Accrued liabilities		(0.1	)

	Total liabilities assumed					(0.1	)

	Total purchase price				$	1.6

PocketSonics
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:


	(in millions)
	Cash				$	0.5
	Goodwill					6.9
	IPR&D					11.5

	Total assets acquired					18.9
	Accounts payable and accrued expenses	$	(0.3	)
	Deferred taxes		(4.1	)

	Total liabilities assumed					(4.4	)

	Total purchase price				$	14.5

Accounts_Receivable_Net_Tables

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Apr. 30, 2015
Components of inventory, net	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:


	(in millions)	As of		As of
		April 30,		July 31,
		2015		2014
	Raw materials	$	70.9	$	59.6
	Work in process		51.3		41.2
	Finished goods		23.1		24

	Total inventory	$	145.3	$	124.8

Inventory_Tables

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Apr. 30, 2015
Components of inventory, net	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:


	(in millions)	As of		As of
		April 30,		July 31,
		2015		2014
	Raw materials	$	70.9	$	59.6
	Work in process		51.3		41.2
	Finished goods		23.1		24

	Total inventory	$	145.3	$	124.8

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
Goodwill and Intangible Assets (Tables)	Apr. 30, 2015
Intangible Assets	Intangible assets are summarized as follows:


					As of April 30, 2015						As of July 31, 2014
	(in millions)		Weighted		Cost		Accumulated		Net		Cost		Accumulated		Net
			Average				Amortization						Amortization
			Amortization
			Period
	Developed technologies			10 years	$	30.3	$	11.5	$	18.8	$	29.6	$	9	$	20.6
	Customer relationships			13 years		44.2		19.1		25.1		43.9		15.1		28.8
	Trade names*			3 years		8.6		0.8		7.8		8.5		0.5		8
	Total intangible assets				$	83.1	$	31.4	$	51.7	$	82	$	24.6	$	57.4

	*	- $7.6 million of trade names are non-amortizable as of April 30, 2015 and July 31, 2014.
Estimated Future Amortization Expense Related to Intangible Assets	The estimated future amortization expense related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:


	(in millions)		Estimated
			Future
			Amortization
			Expense
	2015 (remaining three months)		$	2.2
	2016			8
	2017			7.2
	2018			6.2
	2019			5
	Thereafter			15.5

			$	44.1

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Apr. 30, 2015
Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following table provides the assets and liabilities carried at fair value and measured on a recurring basis at April 30, 2015 and July 31, 2014:


		Fair Value Measurements at April 30, 2015
	(in millions)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets
	Plan assets for deferred compensation	$	4.2	$	4.2	$	-	$	-
	Total assets at fair value	$	4.2	$	4.2	$	-	$	-
	Liabilities
	Contingent consideration	$	2	$	-	$	-	$	2
	Foreign currency forward contracts		0.1		-		0.1		-
	Total liabilities at fair value	$	2.1	$	-	$	0.1	$	2

		Fair Value Measurements at July 31, 2014
	(in millions)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets
	Plan assets for deferred compensation	$	3.6	$	3.6	$	-	$	-
	Total assets at fair value	$	3.6	$	3.6	$	-	$	-
	Liabilities
	Contingent consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Apr. 30, 2015
Changes in Accumulated Other Comprehensive (Loss) Income	The following table summarizes components of Accumulated other comprehensive (loss) income for the nine months ended April 30, 2015:


	(in millions)	Unrealized			Unrealized			Currency			Accumulated
		Losses			Losses on			Translation			Other
		on Foreign			Pension Plan			Adjustment			Comprehensive
		Currency									Income (Loss)
		Forward
		Contracts
	Balance at July 31, 2014	$	-		$	(3.6	)	$	11.4		$	7.8
	Pre-tax change before reclassification to earnings		(0.1	)		-			(10.9	)		(11.0	)
	Income tax benefit		-			-			(0.1	)		(0.1	)
	Balance at April 30, 2015	$	(0.1	)	$	(3.6	)	$	0.4		$	(3.3	)

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	9 Months Ended
Share-based Compensation (Tables)	Apr. 30, 2015
Share-Based Compensation Expense	The following table presents share-based compensation expense included in our Consolidated Statements of Operations:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Cost of product sales		$	0.2		$	0.1		$	0.5		$	0.5
	Cost of engineering sales			0.1			0.1			0.2			0.3
	Research and product development			0.7			0.5			2			2
	Selling and marketing			0.4			0.3			1.1			0.9
	General and administrative			2			1.9			4.6			5
	Total share-based compensation expense before tax			3.4			2.9			8.4			8.7
	Income tax effect			(1.0	)		(0.9	)		(2.5	)		(2.7	)
	Share-based compensation expense included in net income		$	2.4		$	2		$	5.9		$	6

Fair Value of Option Grant Assumptions	The fair value of each option granted during the nine months ended April 30, 2015 and during the three and nine months ended April 30, 2014 was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
			2015			2014			2015			2014
	Expected option term in years (1)			-			5.31			5.31			5.37
	Expected volatility (2)			-			35.1	%		29.3	%		38.6	%
	Risk-free interest rate (3)			-			1.51	%		1.82	%		1.77	%
	Expected annual dividend yield (4)			-			0.42	%		0.56	%		0.52	%
	Weighted average grant date fair value			-		$	30.8		$	19.95		$	27.55

	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk free interest rate for periods equal to the expected term of the stock option is based on the U.S. Treasury yield curve in effect at the time of grant.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
Fair Value of Awards Grant Assumptions	The fair value of our non-GAAP EPS performance-based awards was estimated using the quoted closing price of our common stock on the date of grant. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
			2015			2014			2015			2014
	Stock price (1)		$	87.5		$	94.32		$	71.33		$	77.14
	Expected volatility (2)			27.6	%		27.5	%		29.3	%		27.6	%
	Risk-free interest rate (3)			0.83	%		0.46	%		1	%		0.82	%
	Expected annual dividend yield (4)			0	%		0	%		0	%		0	%
	Weighted average grant date fair value of performance based restricted stock awards		$	127.52		$	117.61		$	88		$	93.85

	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk free interest rate for periods equal to the performance period is based on the U.S. Treasury yield curve in effect at the time of grant.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Tables

Restructuring Charges (Tables)	9 Months Ended
Restructuring Charges (Tables)	Apr. 30, 2015
Summary of Accrued Restructuring Activities	The following table summarizes accrued restructuring activities for the three months ended April 30, 2015:


	(in millions)		Employee			Facility			Total
			Severance			Exit
			and Benefits (A)			Costs (B)
	Balance at January 31, 2015		$	1.1		$	0.5		$	1.6
	Adjustments			(0.1	)		-			(0.1	)
	Cash payments			(0.5	)		(0.1	)		(0.6	)
	Balance at April 30, 2015		$	0.5		$	0.4		$	0.9
	The following table summarizes accrued restructuring activities for the nine months ended April 30, 2015:


	(in millions)		Employee			Facility			Acquisition			Total
			Severance			Exit			Related
			and Benefits (A)			Costs (B)			Charges (B)
	Balance at July 31, 2014		$	2.9		$	0.8		$	0.1		$	3.8
	Adjustments			(0.2	)		(0.1	)		-			(0.3	)
	Cash payments			(2.2	)		(0.3	)		(0.1	)		(2.6	)
	Balance at April 30, 2015		$	0.5		$	0.4		$	-		$	0.9

	(A)	All activity during the period pertains to the 2014 Restructuring Plan.
	(B)	All activity during the period pertains to the 2013 Restructuring Plan.
Restructuring costs, including actions associated with acquisitions
Net Restructuring and Related Charges	Restructuring and related charges, including actions associated with acquisitions, by segment are as follows:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Medical Imaging		$	(0.1	)	$	-		$	(0.2	)	$	(0.2	)
	Ultrasound			-			(0.1	)		(0.1	)		0.4
	Total restructuring and related charges		$	(0.1	)	$	(0.1	)	$	(0.3	)	$	0.2

Restructuring And Other Costs
Net Restructuring and Related Charges	Accrued restructuring charges are classified on the Consolidated Balance Sheets in the following location:


	(in millions)		As of			As of
			April 30,			July 31,
			2015			2014
	Accrued restructuring charges		$	0.8		$	3.4
	Other long-term liabilities			0.1			0.4
	Total restructuring and related charges		$	0.9		$	3.8

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	9 Months Ended
Net Income Per Common Share (Tables)	Apr. 30, 2015
Computation of Basic and Diluted Net Income Per Share	Basic and diluted net income per share are calculated as follows:


		Three Months Ended				Nine Months Ended
		April 30,				April 30,
	(in millions, except share data)	2015		2014		2015		2014
	Net income	$	9.1	$	7.8	$	22.6	$	23.3

	Weighted average number of common shares outstanding-basic (000’s)		12,419		12,403		12,401		12,421
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)		184		244		200		258
	Weighted average number of common shares outstanding-diluted (000’s)		12,603		12,647		12,601		12,679

	Basic net income per share	$	0.73	$	0.63	$	1.82	$	1.88
	Diluted net income per share	$	0.72	$	0.62	$	1.79	$	1.84

	Anti-dilutive shares related to outstanding stock options and unvested restricted stock (000’s)		16		123		179		109

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
Income Taxes (Tables)	Apr. 30, 2015
(Benefit from) Provision for Income Taxes and Effective Tax Rate	The following table presents the (benefit from) provision for income taxes and our effective tax rate for the three and nine months ended April 30, 2015 and 2014:


		Three Months Ended						Nine Months Ended
		April 30,						April 30,
	(in millions)	2015			2014			2015			2014
	(Benefit from) provision for income taxes	$	(1.3	)	$	2.5		$	2.4		$	(6.1	)
	Effective tax rate		-16	%		24	%		10	%		-35	%

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Apr. 30, 2015
Reportable Segment Information	The tables below present information about our reportable segments:


			Three Months Ended						Nine Months Ended
			April 30,						April 30,
	(in millions)		2015			2014			2015			2014
	Product revenue:
	Medical Imaging		$	70.8		$	70.7		$	209		$	208.3
	Ultrasound			37.8			37.3			116.8			112.1
	Security and Detection			21.9			14.1			52.9			49.6
	Total product revenue		$	130.5		$	122.1		$	378.7		$	370
	Engineering revenue:
	Medical Imaging		$	1.1		$	1		$	2.8		$	3.2
	Ultrasound			0.8			-			2			-
	Security and Detection			1.2			1			2.3			2.4
	Total engineering revenue		$	3.1		$	2		$	7.1		$	5.6
	Net revenue:
	Medical Imaging		$	71.9		$	71.7		$	211.8		$	211.5
	Ultrasound			38.6			37.3			118.8			112.1
	Security and Detection			23.1			15.1			55.2			52
	Total net revenue		$	133.6		$	124.1		$	385.8		$	375.6
	Income from operations:
	Medical Imaging		$	8.5		$	8.9		$	25.4		$	19.3
	Ultrasound			(4.2	)		(1.3	)		(7.1	)		(6.1	)
	Security and Detection			3.3			1.8			6.6			3.9
	Total income from operations			7.6			9.4			24.9			17.1
	Total other income, net			0.2			0.9			0.1			0.1
	Income before income taxes		$	7.8		$	10.3		$	25		$	17.2


			As of			As of
			April 30,			July 31,
	(in millions)		2015			2014
	Identifiable assets by segment:
	Medical Imaging		$	191.6		$	218.5
	Ultrasound			230			235.5
	Security and Detection			49			35
	Total reportable segment assets			470.6			489
	Corporate assets (A)			153.9			125.3
	Total assets		$	624.5		$	614.3


			As of			As of
			April 30,			July 31,
	(in millions)		2015			2014
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			55.1			55.1
	Security and Detection (B)			0.4			-
	Total goodwill		$	57.4		$	57

	(A)	Includes cash and cash equivalents of $82.8 million and $60.9 million as of April 30, 2015 and July 31, 2014, respectively.
	(B)	Includes goodwill related to the Pathfinder acquisition as described in Note 3, Business Combinations.

Guarantees_Commitments_and_Con1

Guarantees, Commitments and Contingencies (Tables)	9 Months Ended
	Apr. 30, 2015
Product Warranty Liability	The following table presents our product warranty liability as of April 30, 2015:


	(in millions)	As of
		April 30,
		2015
	Balance at July 31, 2014	$	6
	Provision		4.8
	Settlements made in cash or in kind during the period		(3.6	)
	Balance at April 30, 2015	$	7.2

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)	9 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Sep. 20, 2013	30-May-14	Oct. 28, 2014	Jul. 31, 2014	Apr. 30, 2010
Business Acquisition [Line Items]
Total purchase price	$1,600,000	$10,561,000
Business acquisition, goodwill	57,358,000					56,955,000
PocketSonics
Business Acquisition [Line Items]
Acquisition related charges		100,000
Ownership interests							10.00%
Amount merger consideration paid			11,100,000
Contingent consideration	2,000,000		1,900,000
Business acquisition, goodwill			6,900,000
Loss from pre-acquisition equity interest		500,000
PocketSonics \| Maximum
Business Acquisition [Line Items]
Contingent consideration	3,000,000
PocketSonics \| In-process research and development
Business Acquisition [Line Items]
Amount of equity investment							1,900,000
Intangible assets			11,500,000
Amortization period				10 years
Pathfinder Therapeutics Inc
Business Acquisition [Line Items]
Total purchase price					1,600,000
Weighted average amortization period for intangible assets	7 years 7 months 6 days
Business Acquisition, Goodwill Expected Tax Deductible Period	15 years
Acquisition related charges	100,000
Intangible assets	1,100,000
Business acquisition, goodwill	$400,000

Summary_of_Estimated_Fair_Valu

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Detail) (USD $)	Apr. 30, 2015	Jul. 31, 2014
Business Acquisition [Line Items]
Goodwill	$57,358,000	$56,955,000
Pathfinder Therapeutics Inc
Business Acquisition [Line Items]
Inventory and receivables	200,000
Goodwill	400,000
Intangible assets	1,100,000
Total assets acquired	1,700,000
Accrued liabilities	-100,000
Total liabilities assumed	-100,000
Total purchase price	1,600,000
Pathfinder Therapeutics Inc \| Developed technologies
Business Acquisition [Line Items]
Intangible assets	700,000
Pathfinder Therapeutics Inc \| Customer relationships
Business Acquisition [Line Items]
Intangible assets	300,000
Pathfinder Therapeutics Inc \| Trade names
Business Acquisition [Line Items]
Intangible assets	$100,000

Summary_of_Estimated_Fair_Valu1

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) (Pathfinder Therapeutics Inc)	9 Months Ended
	Apr. 30, 2015
Developed technologies
Business Acquisition [Line Items]
Weighted average useful life	10 years
Customer relationships
Business Acquisition [Line Items]
Weighted average useful life	2 years
Trade names
Business Acquisition [Line Items]
Weighted average useful life	5 years

Summary_of_Fair_Values_of_Sepa

Summary of Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Detail) (USD $)	Apr. 30, 2015	Jul. 31, 2014	Sep. 20, 2013
Business Acquisition [Line Items]
Goodwill	$57,358,000	$56,955,000
PocketSonics
Business Acquisition [Line Items]
Cash			500,000
Goodwill			6,900,000
Total assets acquired			18,900,000
Accounts payable and accrued expenses			-300,000
Deferred taxes			-4,100,000
Total liabilities assumed			-4,400,000
Total purchase price			14,500,000
PocketSonics \| In-process research and development
Business Acquisition [Line Items]
Intangible assets			$11,500,000

Accounts_Receivable_Net_Additi

Accounts Receivable, Net - Additional Information (Detail) (Sales Revenue, Net, Largest customers)	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Sales Revenue, Net \| Largest customers
Accounts Receivable [Line Items]
Percentage of total net revenue	68.00%	68.00%	64.00%	67.00%

Percentage_of_Net_Product_and_

Percentage of Net Product and Engineering Revenue from Major Customers (Detail) (Sales Revenue, Net, Largest customers)	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	68.00%	68.00%	64.00%	67.00%
Philips
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	15.00%	17.00%	13.00%	17.00%
Siemens AG
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	11.00%	12.00%	12.00%	11.00%
Toshiba
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	12.00%	10.00%	12.00%	11.00%
L-3
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	15.00%	12.00%	13.00%	11.00%

Summary_of_Net_Accounts_Receiv

Summary of Net Accounts Receivable Greater Than or Equal to 10% of Net Account Receivable Balance (Detail) (Accounts Receivable, Credit Concentration Risk)	0 Months Ended
	Apr. 30, 2015	Jul. 31, 2014
Philips
Accounts Receivable [Line Items]
Percentage of net accounts receivable	18.00%	16.00%
L-3
Accounts Receivable [Line Items]
Percentage of net accounts receivable	20.00%	16.00%
Toshiba
Accounts Receivable [Line Items]
Percentage of net accounts receivable		11.00%

Summary_of_Net_Accounts_Receiv1

Summary of Net Accounts Receivable Greater Than or Equal to 10% of Net Account Receivable Balance (Parenthetical) (Detail) (Maximum, Largest customers, Accounts Receivable)	0 Months Ended
	Apr. 30, 2015
Maximum \| Largest customers \| Accounts Receivable
Accounts Receivable [Line Items]
Percentage of net accounts receivable	10.00%

Components_of_Inventory_Detail

Components of Inventory (Detail) (USD $)	Apr. 30, 2015	Jul. 31, 2014
Inventory [Line Items]
Raw materials	$70,900,000	$59,600,000
Work in process	51,300,000	41,200,000
Finished goods	23,100,000	24,000,000
Total inventory	$145,251,000	$124,777,000

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Line Items]
Goodwill	$57,358,000		$57,358,000		$56,955,000
Acquisition of goodwill			400,000
Amortization expense related to acquired intangible assets	$2,200,000	$1,900,000	$6,600,000	$5,700,000
Minimum
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets, estimated useful lives			1 year
Maximum
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets, estimated useful lives			14 years

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	9 Months Ended
Intangible Assets (Detail) (USD $)	Apr. 30, 2015		Jul. 31, 2014
Intangible Assets by Major Class [Line Items]
Cost	$83,100,000		$82,000,000
Accumulated Amortization	31,400,000		24,600,000
Net	51,738,000		57,366,000
Developed technologies
Intangible Assets by Major Class [Line Items]
Weighted-Average Amortization Period	10 years
Cost	30,300,000		29,600,000
Accumulated Amortization	11,500,000		9,000,000
Net	18,800,000		20,600,000
Customer relationships
Intangible Assets by Major Class [Line Items]
Weighted-Average Amortization Period	13 years
Cost	44,200,000		43,900,000
Accumulated Amortization	19,100,000		15,100,000
Net	25,100,000		28,800,000
Trade names
Intangible Assets by Major Class [Line Items]
Weighted-Average Amortization Period	3 years	[1]
Cost	8,600,000	[1]	8,500,000	[1]
Accumulated Amortization	800,000	[1]	500,000	[1]
Net	$7,800,000	[1]	$8,000,000	[1]

[1]	$7.6 million of trade names are non-amortizable as of April 30, 2015 and July 31, 2014.

Intangible_Assets_Parenthetica

Intangible Assets (Parenthetical) (Detail) (USD $)	Apr. 30, 2015	Jul. 31, 2014
In Millions, unless otherwise specified	Apr. 30, 2015	Jul. 31, 2014
Intangible Assets by Major Class [Line Items]
Non-Amortizable Trade names, cost	$7.60	$7.60

Estimated_Future_Amortization_

Estimated Future Amortization Expense Related to Intangible Assets (Detail) (USD $)	Apr. 30, 2015
In Millions, unless otherwise specified	Apr. 30, 2015
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
2015 (remaining three months)	$2.20
2016	8
2017	7.2
2018	6.2
2019	5
Thereafter	15.5
Finite-Lived Intangible Assets, Net, Total	$44.10

Assets_and_Liabilities_Carried

Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Apr. 30, 2015	Jul. 31, 2014
In Millions, unless otherwise specified	Apr. 30, 2015	Jul. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Plan assets for deferred compensation	$4.20	$3.60
Total assets at fair value	4.2	3.6
Contingent consideration	2	2.1
Foreign currency forward contracts	0.1
Total liabilities at fair value	2.1	2.1
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Plan assets for deferred compensation	4.2	3.6
Total assets at fair value	4.2	3.6
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	0.1
Total liabilities at fair value	0.1
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	2	2.1
Total liabilities at fair value	$2	$2.10

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2015	Apr. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration	$0	($62)	$183

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (Forward Contracts)	Apr. 30, 2015	Apr. 30, 2015	Jul. 31, 2014	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
	USD ($)	CAD	USD ($)	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses
				USD ($)	USD ($)	USD ($)	USD ($)
Derivative [Line Items]
Notional amount of cash flow hedge instruments		2,700,000	$0
Unrealized loss on cash flow hedges	100,000
Realized gains (losses) on cash flow hedge instruments				($300,000)	$100,000	($300,000)	($200,000)

Common_Stock_Repurchases_Addit

Common Stock Repurchases - Additional Information (Detail) (2014 Repurchase program, USD $)	3 Months Ended	9 Months Ended	11 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2015	Apr. 30, 2015	Jun. 02, 2014
Stockholders Equity Note [Line Items]
Repurchase of common stock (in shares)	37,840	132,323	151,006
Repurchase of common stock	$3.30	$10.20	$11.70
Average purchase price of common stock	$86.68	$77.37	$77.23
Maximum
Stockholders Equity Note [Line Items]
Stock Repurchase Program, Authorized Amount				$30

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive (Loss) Income (Detail) (USD $)	9 Months Ended
	Apr. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning balance	$7,805,000
Pre-tax change before reclassification to earnings	-11,000,000
Income tax benefit	-100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending balance	-3,264,000
Unrealized Losses on Pension Plan
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning balance	-3,600,000
Income tax benefit	0
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending balance	-3,600,000
Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning balance	11,400,000
Pre-tax change before reclassification to earnings	-10,900,000
Income tax benefit	-100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending balance	400,000
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Pre-tax change before reclassification to earnings	-100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending balance	($100,000)

Sharebased_Compensation_Expens

Share-based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	$3.40	$2.90	$8.40	$8.70
Income tax effect	-1	-0.9	-2.5	-2.7
Share-based compensation expense included in net income	2.4	2	5.9	6
Cost of product sales
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	0.2	0.1	0.5	0.5
Cost of Engineering Sales
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	0.1	0.1	0.2	0.3
Research and Product Development
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	0.7	0.5	2	2
Selling and Marketing
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	0.4	0.3	1.1	0.9
General and Administrative
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share-based compensation expense before tax	$2	$1.90	$4.60	$5

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	0	78,846
Intrinsic value of options exercised	$2.50	$4.20
Total fair value of restricted stock units vested in period	1.1	6.5
Stock Option and Restricted Stock Bonus Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements	12.7	12.7
Unrecognized compensation cost related to non-vested share-based compensation arrangements, weighted average period		1 year 4 months 24 days
Non-GAAP EPS Performance-Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	265	36,641
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vested or expected to vest, shares	295,878	295,878
Stock options exercisable, shares	143,207	143,207
Stock options vested or expected to vest, weighted average exercise price	$68.50	$68.50
Stock options exercisable, weighted average exercise price	$63.52	$63.52
Stock options vested or expected to vest, aggregate intrinsic value	4.7	4.7
Stock options exercisable, aggregate intrinsic value	$3	$3
Stock options vested or expected to vest, weighted average remaining contractual term		5 years 26 days
Stock options exercisable, weighted average remaining contractual term		4 years 4 months 13 days
Total Shareholders Return Performance-based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	206	28,455

Fair_Value_of_Option_Grant_Ass

Fair Value of Option Grant Assumptions (Detail) (USD $)	3 Months Ended				9 Months Ended
Fair Value of Option Grant Assumptions (Detail) (USD $)	Apr. 30, 2015		Apr. 30, 2014		Apr. 30, 2015		Apr. 30, 2014
Stock Options
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected option term in years			5 years 3 months 22 days	[1]	5 years 3 months 22 days	[1]	5 years 4 months 13 days	[1]
Expected volatility			35.10%	[2]	29.30%	[2]	38.60%	[2]
Risk-free interest rate			1.51%	[3]	1.82%	[3]	1.77%	[3]
Expected annual dividend yield			0.42%	[4]	0.56%	[4]	0.52%	[4]
Weighted average grant date fair value			$30.80		$19.95		$27.55
Total Shareholders Return Performance-based Awards
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Stock Price	$87.50	[5]	$94.32	[5]	$71.33	[5]	$77.14	[5]
Expected volatility	27.60%	[6]	27.50%	[6]	29.30%	[6]	27.60%	[6]
Risk-free interest rate	0.83%	[7]	0.46%	[7]	1.00%	[7]	0.82%	[7]
Expected annual dividend yield	0.00%	[8]	0.00%	[8]	0.00%	[8]	0.00%	[8]
Weighted average grant date fair value of performance based restricted stock awards	$127.52		$117.61		$88		$93.85

[1]	The expected option term was estimated using historical data.
[2]	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
[3]	The risk free interest rate for periods equal to the expected term of the stock option is based on the U.S. Treasury yield curve in effect at the time of grant.
[4]	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
[5]	The stock price is the closing price of our common stock on the date of grant.
[6]	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
[7]	The risk free interest rate for periods equal to the performance period is based on the U.S. Treasury yield curve in effect at the time of grant.
[8]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Fair_Value_of_Option_Grant_Ass1

Fair Value of Option Grant Assumptions (Parenthetical) (Detail) (Total Shareholders Return Performance-based Awards)	3 Months Ended				9 Months Ended
	Apr. 30, 2015		Apr. 30, 2014		Apr. 30, 2015		Apr. 30, 2014
Total Shareholders Return Performance-based Awards
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected annual dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]	0.00%	[1]

[1]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges	($107,000)	($80,000)	($317,000)	$216,000
Fiscal Year 2013 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges			-100,000
Restructuring charges incurred to date	4,000,000		4,000,000
Fiscal Year 2014 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$2,600,000		($200,000)

Summary_of_Charges_Related_to_

Summary of Charges Related to Accrued Restructuring Activity (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015		Apr. 30, 2015
Restructuring Cost and Reserve [Line Items]
Balance at beginning period	$1.60		$3.80
Adjustments	-0.1		-0.3
Cash payments	-0.6		-2.6
Balance at end period	0.9		0.9
Employee Severance and Benefits
Restructuring Cost and Reserve [Line Items]
Balance at beginning period	1.1	[1]	2.9	[1]
Adjustments	-0.1	[1]	-0.2	[1]
Cash payments	-0.5	[1]	-2.2	[1]
Balance at end period	0.5	[1]	0.5	[1]
Facility Exit Costs
Restructuring Cost and Reserve [Line Items]
Balance at beginning period	0.5	[2]	0.8	[2]
Adjustments			-0.1	[2]
Cash payments	-0.1	[2]	-0.3	[2]
Balance at end period	0.4	[2]	0.4	[2]
Acquisition Related Charges
Restructuring Cost and Reserve [Line Items]
Balance at beginning period			0.1	[2]
Cash payments			($0.10)	[2]

[1]	All activity during the period pertains to the 2014 Restructuring Plan.
[2]	All activity during the period pertains to the 2013 Restructuring Plan.

Restructuring_and_Related_Char

Restructuring and Related Charges by Segment (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	($107)	($80)	($317)	$216
Medical Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	-100		-200	-200
Ultrasound
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net		($100)	($100)	$400

Location_of_Restructuring_Char

Location of Restructuring Charges Classified on Consolidated Balance Sheets (Detail) (USD $)	Apr. 30, 2015	Jan. 31, 2015	Jul. 31, 2014
In Millions, unless otherwise specified	Apr. 30, 2015	Jan. 31, 2015	Jul. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$0.90	$1.60	$3.80
Accrued Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	0.8		3.4
Other long-term liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$0.10		$0.40

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Net income	$9,124	$7,790	$22,608	$23,329
Weighted-average number of common shares outstanding-basic	12,419	12,403	12,401	12,421
Effect of dilutive securities:
Stock options and restricted stock units	184	244	200	258
Weighted-average number of common shares outstanding-diluted	12,603	12,647	12,601	12,679
Basic net income per share	$0.73	$0.63	$1.82	$1.88
Diluted net income per share	$0.72	$0.62	$1.79	$1.84
Anti-dilutive shares related to outstanding stock options and unvested restricted stock	16	123	179	109

Benefit_from_Provision_for_Inc

(Benefit from) Provision for Income Taxes and Effective Tax Rate (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Provision For Income Taxes [Line Items]
(Benefit from) provision for income taxes	($1,286)	$2,509	$2,437	($6,089)
Effective tax rate	-16.00%	24.00%	10.00%	-35.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014	Jul. 31, 2014
Income Taxes [Line Items]
U.S. Federal statutory tax rate	35.00%	35.00%	35.00%	35.00%
Discrete tax benefit	$2.90		$3.70	$10.60
Discrete tax items, favorable changes in reserves for uncertain tax positions	3	0.2	3
Discrete tax items, miscellaneous favorables/unfavorable	-0.1	0.4	-0.1
Remeasurement of tax reserves on a reduction in uncertain federal tax credits for R&D			0.8	0.9
Discrete tax items, unfavorable adjustment to a deferred item related to equity compensation		0.6
Reduction of taxes from change in branch accounting for Canadian operations				8.8
Other items				0.9
Unrecognized tax benefits, accrued interest and penalties	0.3		0.3		0.6
Unrecognized tax benefits, for uncertain tax positions	$4.40		$4.40

Segment_Information_Additional

Segment Information - Additional Information (Detail)	9 Months Ended
	Apr. 30, 2015
	Segment
Segment Reporting Information [Line Items]
Number of segments	3

Reportable_Segment_Information

Reportable Segment Information (Detail) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015		Apr. 30, 2014	Apr. 30, 2015		Apr. 30, 2014	Jul. 31, 2014
Product revenue:
Product Revenue	$130,479		$122,067	$378,686		$369,992
Engineering revenue:
Engineering Revenue	3,080		1,965	7,134		5,559
Net Revenue:
Total net revenue	133,559		124,032	385,820		375,551
Income from operations:
Income (loss) from operations	7,637		9,417	24,895		17,136
Total other income, net	201		882	150		104
Income before income taxes	7,838		10,299	25,045		17,240
Identifiable assets by segment:
Assets	624,536			624,536			614,342
Goodwill by segment:
Goodwill	57,358			57,358			56,955
Reportable segments
Identifiable assets by segment:
Assets	470,600			470,600			489,000
Corporate
Identifiable assets by segment:
Assets	153,900	[1]		153,900	[1]		125,300	[1]
Medical Imaging
Product revenue:
Product Revenue	70,800		70,700	209,000		208,300
Engineering revenue:
Engineering Revenue	1,100		1,000	2,800		3,200
Net Revenue:
Total net revenue	71,900		71,700	211,800		211,500
Income from operations:
Income (loss) from operations	8,500		8,900	25,400		19,300
Medical Imaging \| Reportable segments
Identifiable assets by segment:
Assets	191,600			191,600			218,500
Goodwill by segment:
Goodwill	1,900			1,900			1,900
Ultrasound
Product revenue:
Product Revenue	37,800		37,300	116,800		112,100
Engineering revenue:
Engineering Revenue	800			2,000
Net Revenue:
Total net revenue	38,600		37,300	118,800		112,100
Income from operations:
Income (loss) from operations	-4,200		-1,300	-7,100		-6,100
Ultrasound \| Reportable segments
Identifiable assets by segment:
Assets	230,000			230,000			235,500
Goodwill by segment:
Goodwill	55,100			55,100			55,100
Security and Detection
Product revenue:
Product Revenue	21,900		14,100	52,900		49,600
Engineering revenue:
Engineering Revenue	1,200		1,000	2,300		2,400
Net Revenue:
Total net revenue	23,100		15,100	55,200		52,000
Income from operations:
Income (loss) from operations	3,300		1,800	6,600		3,900
Security and Detection \| Reportable segments
Identifiable assets by segment:
Assets	49,000			49,000			35,000
Goodwill by segment:
Goodwill	$400	[2]		$400	[2]

[1]	Includes cash and cash equivalents of $82.8 million and $60.9 million as of April 30, 2015 and July 31, 2014, respectively.
[2]	Includes goodwill related to the Pathfinder acquisition as described in Note 3, Business Combinations.

Reportable_Segment_Information1

Reportable Segment Information (Parenthetical) (Detail) (USD $)	Apr. 30, 2015	Jul. 31, 2014	Apr. 30, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified	Apr. 30, 2015	Jul. 31, 2014	Apr. 30, 2014	Jul. 31, 2013
Segment Reporting Information [Line Items]
Cash and cash equivalents	$119,835	$114,540	$119,448	$113,033
Corporate
Segment Reporting Information [Line Items]
Cash and cash equivalents	$82,800	$60,900

Guarantees_Commitments_and_Con2

Guarantees, Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Oct. 11, 2011	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014	Jul. 31, 2014
Commitments and Contingencies Disclosure [Line Items]
Liabilities related to agreements		$0		$0
Revolving credit agreement period	5 years
Business exit cost		300,000	400,000	1,400,000	1,300,000
Product Extended Warranty Contracts
Commitments and Contingencies Disclosure [Line Items]
Deferred revenue for product extended warranty contracts		5,600,000		5,600,000		7,400,000
Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Credit facility maximum borrow capacity	100,000,000
Credit facility, expiry date	10-Oct-16
Percentage of capital stock pledge as collateral	65.00%
Leverage ratio		0.40%		0.40%
Credit facility transaction costs incurred		500,000		500,000
Credit facility, maturity period				5 years
Line of credit amount outstanding		0		0		0
Revolving Credit Facility \| Other Revolving Credit Facilities
Commitments and Contingencies Disclosure [Line Items]
Credit facility available borrowing capacity		1,200,000		1,200,000		4,400,000
Minimum
Commitments and Contingencies Disclosure [Line Items]
Standard product warranty term				12 months
Minimum \| Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Credit facility commitment fee percentage	0.20%
Interest coverage ratio		300.00%		300.00%
Minimum \| Revolving Credit Facility \| LIBOR Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate	1.25%
Minimum \| Revolving Credit Facility \| Base Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate	0.00%
Maximum
Commitments and Contingencies Disclosure [Line Items]
Standard product warranty term				60 months
Maximum \| Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Aggregate available credit amount under specified circumstances	150,000,000
Credit facility commitment fee percentage	0.35%
Leverage ratio of total debt to earnings before interest, taxes, depreciation, and amortization or EBITDA				275.00%
Maximum \| Revolving Credit Facility \| LIBOR Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate	2.00%
Maximum \| Revolving Credit Facility \| Base Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate	1.00%

Product_Warranty_Liability_Det

Product Warranty Liability (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015
Product Liability Contingency [Line Items]
Beginning balance	$6
Provision	4.8
Settlements made in cash or in kind during the period	-3.6
Ending balance	$7.20

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event, USD $)	0 Months Ended
	Jun. 01, 2015
Subsequent Event
Subsequent Event [Line Items]
Dividend declaration date	1-Jun-15
Dividend declared	$0.10
Dividend payable date	29-Jun-15
Dividend record date	15-Jun-15